Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 2/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 7/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891748 | 0.86 | CNR2 (0.38) | NOTUMHDAC1HDAC8HDAC6SRD5A1 | |
| SCHEMBL16480401 | 0.82 | NOTUM (0.54) | NOTUMCCR2CCR1CCR5HDAC1 | |
| SCHEMBL9893095 | 0.78 | NOTUM (0.50) | NOTUMCCR2CCR1CCR5HDAC1 | |
| SCHEMBL24717003 | 0.76 | HDAC1 (0.40) | CCR2CCR1HDAC1HDAC8HDAC6 | |
| SCHEMBL9108102 | 0.76 | NOTUM (0.50) | NOTUMCCR2CCR1CCR5HDAC1 | |
| SCHEMBL9108096 | 0.76 | NOTUM (0.50) | NOTUMCCR2CCR1CCR5HDAC1 | |
| SCHEMBL9891746 | 0.71 | CNR2 (0.45) | KMT2A | |
| SCHEMBL9892165 | 0.69 | CNR2 (0.75) | — | |
| SCHEMBL16253054 | 0.69 | CNR2 (0.47) | CCR2CCR1SRD5A1 | |
| SCHEMBL9891749 | 0.68 | CYP2D6 (0.34) | NOTUMSRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | NOTUM 2241/4885CCR2 6/4885CCR1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.